New treatment for rare autoimmune disease of nerve cells

EMA has recommended granting a marketing authorisation in the European Union (EU) for Enspryng (satralizumab) for the treatment of neuromyelitis optica spectrum disorders (NMOSD) in adults and adolescents from 12 years of age who are positive for anti-aquaporin-4 antibodies (AQP4-IgG). Read full article: https://www.ema.europa.eu/en/news/new-treatment-rare-autoimmune-disease-nerve-cells

Nicotine e-cigarettes laws are changing

If you currently use nicotine e-cigarettes, you need to be aware that from 1 October 2021 you will no longer be able to legally buy these products from overseas websites without first talking with a GP and getting a prescription. The main reason a GP may provide a prescription is for the purposes of smoking […]